Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.39
- Piotroski Score 4.00
- Grade Buy
- Symbol (ATRC)
- Company AtriCure, Inc.
- Price $37.46
- Changes Percentage (0.27%)
- Change $0.1
- Day Low $37.07
- Day High $38.27
- Year High $43.00
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $81.00
- Low Stock Price Target $26.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.80
- Trailing P/E Ratio -28.02
- Forward P/E Ratio -28.02
- P/E Growth -28.02
- Net Income $-30,438,000
Income Statement
Quarterly
Annual
Latest News of ATRC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
AtriCure Inc (ATRC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Michael Carrel, President and CEO, discussed ongoing trends in PFA's impact on MIS Ablation and Clip businesses. New products are influencing current trends, with an expected rise in patients needing ...
By Yahoo! Finance | 1 week ago -
Shareholders in AtriCure (NASDAQ:ATRC) are in the red if they invested three years ago
AtriCure, Inc. (NASDAQ:ATRC) shares rose 17% in the last quarter, but over the past three years, they fell by 61%. Despite revenue growth of 19% annually, the stock experienced a 17% compound loss....
By Yahoo! Finance | 3 weeks ago -
Here's Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
TimesSquare Capital Management released its U.S. Small Cap Growth Strategy Q2 2024 investor letter, showing a -1.59% return. AtriCure, Inc. (NASDAQ:ATRC) was highlighted as a stock pick, with a 18....
By Yahoo! Finance | 1 month ago
